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Abstract 
Purpose: Glioblastoma multiforme 
(GBM) remains one of the most 
devastating diseases known to mankind 
and affects more than 17,000 patients in 
the United States alone every year. This 
malignancy infiltrates the brain early in its 
course and makes complete neurosurgical 
resection almost impossible. Recent years 
have brought significant advances in tumor 
biology. Many cancers, including gliomas, 
appear to be supported by cells with stem-
like properties. Nanoparticles are excellent 
candidates to serve as delivery vectors of 
drugs or biologically active molecules 
because of their unique chemical and 
physical properties that result in specific 
transportation and deposition of such 
agents in specific organs and tissues.. 
 In the current study we have 
investigated the in vitro action of 
nanostructural systems (temozolomide 
encapsulated in chitosan and polymer 
nanostructures) on high-grade glioma-
derived cancer stem cells (CSCs), with the 
intention of developing a new therapy to 
treat specific brain tumors with increased 
efficacy and minimal toxicity. In vitro 
cytotoxicity and apoptosis measurements 
indicated that the drug/vector combination 
facilitated the ability of the alkylating drug 
TMZ to alter the resistance of these cancer 
stem cells, suggesting a new chemotherapy 
strategy even for patients diagnosed with 
inoperable or recurrent malignant gliomas  
Methods: At the National Institute for 
R & D of Isotopic and Molecular 
Technologies form Cluj Napoca were 
synthesized three types of nanostructures 
chitosan-TMZ, TMZ-chitosan-PEG (poly-
ethylene glycol), TMZ-chitosan-PPG 
(polypropylene glycol). Three type of cell 
lines (Glioma-derived stem, HFL and 
HUVEC) were treated with the 3 types of 
nanostructures and the survival rate of the 
cells was compare to standard therapy 
(TMZ). 
Results: The results showed a reduction 
in the rate of survival of the tumor cells. 
Cell proliferation assays clearly 
demonstrate the differences between 
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conventional chemotherapy (TMZ) and 
temozolomide encapsulated in chitosan 
and polymer nanostructures.       
Conclusion: Nanostructures like 
chitosan, PEG, PPG are useful as vectors 
for drugs transport. 
Despite combined therapy (surgery, 
radiotherapy, chemotherapy), currently 
median patient survival is reduced. The 
key to improving life expectancy could be 
an effective therapy targeted, customized 
for each case. An increasingly important 
role will be new methods of treatment such 
as immunotherapy, gene therapy or 
nanotherapy. 
Key words: malignant gliomas, primary 
tumor cell culture, temozolomide. 
Introduction 
Malignant gliomas are responsible for 
the death of approximately 11,000 patients 
per year.[1] The standard care for patients 
diagnosed with high-grade central nervous 
systems (CNS) gliomas include, post-
operatively, temozolomide (TMZ) 
concomitant and adjuvant to radiotherapy. 
This therapeutic strategy is, however, 
associated with high toxicity, limited 
efficiency and significant side effects. The 
median length of survival for patients with 
high-grade primary glial tumors ranges 
from 11 to 33 months after initial 
diagnosis and an average of 7 months 
following recurrence.[2,3] 
The failure of current approaches to the 
treatment of malignant gliomas has been 
attributed to the existence of a sub-
population of cancer cells malignant 
glioma cancer stem cells (CSCs), which 
have the ability to withstand 
chemotherapeutics and ionizing radiation 
based on certain of their unique properties: 
high expression of anti-apoptotic proteins, 
high expression of ABC pumps, and 
remarkable DNA repair capability. [4-6] 
Traditional therapies, such as DNA 
alkylating or methylating drugs along with 
radiation oncology treatments, have low 
treatment efficacy for these cell types. 
More complex treatments capable of 
overcoming the CSCs’ ability to eliminate 
anti-cancer drugs and perform other 
protective functions are therefore critically 
needed. For this reason, a combination of 
traditional treatments and nanotechnology-
based approaches offers attractive 
possibilities. More efficient and less toxic 
therapeutics that can cross the CSCs 
protective barriers are urgently needed. In 
this context, nanomaterials could play an 
important role based on their unique 
electronic, optical, magnetic, and structural 
properties that are found neither in bulk 
materials nor in single molecules and 
which are necessary to develop advanced 
cancer treatments.  
Theoretical considerations of nanotherapy 
Nanoparticles are biodegradable or 
bioresistence polymer matrix, with an 
average diameter of approx. 200 nm. 
Nanoparticles are obtained by 
polymerization of monomers or directly 
from the processed polymer. 
The advantages of nanoparticles are: 
relatively simple preparation, they ensure 
protection of the active principles from 
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chemical and enzymatic degradation 
(nanocapsules) limiting side effects of 
active substances and provide 
transportation and release to the target by 
the biodegradable matrix. Disadvantages 
are the high costs of technology 
(equipment, raw materials) and toxicity of 
adjuvants [7]. 
A large area relative to their volume, 
increased bioavailability, provide controlled 
release of the active substance and support 
the intracellular and molecular vectors. 
Due to the extremely small size, 
nanoparticles vectors easily cross biological 
barriers (blood-brain barrier in our 
case)[8]. 
Theoretical considerations of nanotherapy 
in brain tumors 
Molecular nanodiagnostic. Nanoparticles 
increased sensitivity and specificity for 
high-resolution noninvasive medical 
imaging, at molecular and cellular level 
(ultrasound, CT, MRI, OI. PET). (PEG-
chitosan-clorotoxin-fluoroscopic agent 
nanoparticles may improve the resolution 
by 10 times)[9]. 
Nanovaccines are useful for 
immunotherapy, nanoantibiotherapy offers 
a lower risk of developing resistance to 
antibiotics and some nanostructures can be 
used in neuronal nanoprotection [10]. 
Transport nanosystems for gene therapy 
(to replace viruses as vectors) are less likely 
immunologic and allow the transfer of 
large quantities of genetic material. A 
polyglycerol dendrimer polymer has been 
shown to improve RNA stability and 
accumulation in brain tumors in 
animals[7]. 
Antitumoral nanotherapy PEG 
dimethacrylate methyl ether methacrylate 
and iron oxide nanostructures can be used 
as a biomaterial for the thermal treatment 
of GBM. Many types of nanoparticles such 
as biodegradable polymers (PEG, PPG, 
PBCA) lactic acid loaded with different 
type of chemotherapy agents increased 
tumor cytotoxicity and survival in 
laboratory animals with decreased side 
effects of cytostatic. Use of nanoparticles 
can increase the effectiveness of 
radiotherapy with decrease of side effects 
[11]. 
Methods 
At the National Institute for R & D of 
Isotopic and Molecular Technologies form 
Cluj Napoca were synthesized three types 
of nanostructures chitosan-TMZ, TMZ-
chitosan-PEG (poly-ethylene glycol), TMZ-
chitosan-PPG (polypropylene glycol).  
Chitosan [poly(b-(10/4)-2-amino-2-
deoxy-Dglucose)] is a natural cationic 
polysaccharide derived from chitin, which 
is copolymer, a glucosamine and an N-
acetyl glucosamine units, combined 
together [12]. Chitosan is being widely 
used as a pharmaceutical excipient, 
comprising a series of polymers varying in 
their degree of deacylation, molecular 
weight, viscosity, pKa etc. The presence of 
a number of amino groups permits CTS to 
chemically react with anionic systems, 
thereby resulting in alteration of 
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physicochemical characteristics of reactants 
and developing new properties of such 
combinations [1]. 
Temozolomide (brand names Temodar 
and Temodal and Temcad) is an oral 
alkylating agent used for the standard 
treatment of Grade IV astrocytoma. 
 
 
Chitosan structural formula 
 
 
PEG poly-ethylene-glycol 
 
 
PPG poly-propylene-glycol 
 
 
Structural formula of temozolomide 
 
 
PEG + chitosan + Tz (micrometer structures of 
chitosan with poly-ethylene-glycol and 
temozolomide.. Spheres of 5-15 microns) 
 
PPG + chitosan + Tz (micrometer structures of 
chitosan poly-propylene glycol and temozolomide 
filaments with a length of 10-50 microns) 
 
 
chitosan + Tz (structures of chitosan and 
temozolomide, sub-micrometer (nanometer) 
spheroids) 
 
Chitosan (CTS) from crab shells with 
85% deacetylation degree, poly-ethylene-
glycol, poly-propylene-glycol, were 
purchased from Sigma Aldrich.  
CTS was dissolved in 1% (v/v) acetic 
acid aqueous solution stirring for 6 hours 
at 300C temperature, at final the solution 
being pale yellow, with a homogenous 
consistence and aspect. The CTS solution 
was split in 5 equal volumes, 50 ml each, 
and to each CTS sample was added 0,5 ml 
linking additive agent and 10 mg powder 
from Temodal. Calculations assured that 
each sample contains 10 mg TMZ. 
We obtain a temozolomide 
concentration of 50 micromol/l . 
The solutions were further stirred for 30 
min and then ultrasonically treated in an 
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Elmasonic E60H ultrasonic bath for 360 
min. 
Microspheres of CTS-based 
polyelectrolyte complex containing 
TMZ/linker were characterized by FTIR 
electronic microscope connected to FTIR 
JASCO 6100 spectrometer. 
The malignant glioma cancer stem cells 
(CSCs), used in this study were isolated 
from a glioblastoma multiforme biopsy. 
Briefly, after mechanical dissociation of 
tumor tissue, the fragments were placed in 
1 ml of fetal calf serum (FCS). After three 
hours, 3 ml of DMEM/F-12 medium 
supplemented with 15% FCS was added to 
the dish. After reaching a subconfluent 
monolayer, cells were detached using 
trypsin/ EDTA and resuspended in a 
serum-free media: DMEM/F12 (1:1) 
medium, supplemented with 15 ng/ml 
basic fibroblast growth factor (bFGF), 20 
ng/ml epidermal growth factor (EGF), 
2mM/l L-glutamine, 4 U/l insulin growth 
factor-1 (IGF-1) and B 27 supplement 
(1:50) (Sigma Aldrich). Isolated and 
expanded cells revealed some stem-cell 
specific features, such as the expression of 
cellular markers (CD133, CD105, CD90, 
Nanog, Oct ¾ (immunocytochemistry) 
expression of specific genes, such as : 
CXCR4, nestin, glial fibrillary acidic 
protein (GFAP), and neurofilament 
protein (NF) (reverse transcription-PCR). 
Cells also displayed a high proliferative 
potential despite chemotherapy and 
irradiation and also had the ability to form 
spheroids in suspension.  
The three type of cell lines (Glioma-
derived stem, HFL-Normal fibroblasts 
human isolated from lung and endothelial 
cell line HUVEC-Human Umbilical Vein 
endothelial cell.) were treated with the 3 
types of nanostructures and the survival 
rate of the cells was compare to standard 
therapy (TMZ). 
We used three cell lines to study the 
difference between tumor cells and normal 
cell lines (fibroblasts and endothelial cells). 
The four compounds (PEG + chitosan + 
Tz, Tz + PPG + chitosan, chitosan + Tz 
and TZ) after binding were filtered 
through a 220nm filter sterilized  
Stem cells are in the exponential phase 
of cell growth they are detached by 
exposure for 5 min in 0.25% trypsin 
EDTA after 3 washes with PBS. Trypsin is 
inactivated by the addition of culture 
medium with 10% fetal calf serum, and the 
cell suspension centrifuged 5 min at 1100 
rpm. Cell viability is checked by trypan 
blue 0.4%. The cells are counted with a 
Thoma chamber. 
The 3 cell lines (GM 1, HFL and 
HUVEC) after being counted are seeded in 
96-well plates each 7500 cells / well and 
suspended in 200 ml medium; after 24 h 
cells were subjected to treatment that 
joined us and after a further 24 hours 
MTT assay was performed 
MTT test. Twenty-four hours after 
therapy culture medium was aspirated and 
the cells will be exposed to 100 ml solution 
of MTT 1mg/ml (tetrazolium Bromide 
Thyazolyl Blue) for 1 hour at 37 ° C. MTT 
is a tetrazolium salt which is converted in 
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cellular mitochondria of viable cells into a 
formazan compound dark blue colored, 
insoluble in aqueous solutions. After the 
incubation period, MTT solution is 
aspirated from the wells and formazan 
crystals were dissolved with DMSO 
150µl/well (dimethyl sulfoxide) obtaining 
a color reaction. For measuring the optic 
density, boards are analyzed at 492 nm 
using a plate reader BioTek Synergy2. 
Each determination shall be made in 
triplicate. 
Statistical analysis 
Statistical significance values were 
obtained using a one-way analysis of 
variance (ANOVA), with 95% confidence 
(C.I.) level, using GraphPad Prism 5 
statistics program (GraphPad Inc, San 
Diego, CA, USA). Bonferroni’s multiple 
comparison test was considered statistically 
significant at p <0.05. All experiments were 
performed in triplicate. 
Results 
In our experiments,. there was an 
impotant difference between TMZ alone 
(at the same concentration) and the 
control sample on the one hand and the 
three types of nanostructures studied (PEG 
+ chitosan + Tz, Tz + PPG + chitosan, 
chitosan + Tz) on the other hand for each 
cell type (Glioma-derived stem, HFL and 
HUVEC). Figure 1 
 
 
Figure 1 
Survival chemotherapy graphics for the three type of cell lines (Glioma-derived stem, HFL-Normal fibroblasts 
human isolated from lung and endothelial cell line HUVEC-Human Umbilical Vein endothelial cell.) treated 
with the 3 types of nanostructures and standard therapy (TMZ). The vertical axis represents the optical density 
(remaining cell population) and the horizontal axis the various therapy options. 
 
HFL 
Bonferroni's Multiple Comparison Test 
Mean 
Diff. t 
Significant? 
P < 0.05? Summary 95% CI of diff 
Ctrl vs PEG+CTS+TMZ 0.3903 20.68 Yes *** 0.3282 to 0.4523 
Ctrl vs PPG+CTS+TMZ 0.5728 30.35 Yes *** 0.5107 to 0.6348 
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Ctrl vs CTS+TMZ 0.3183 16.86 Yes *** 0.2562 to 0.3803 
Ctrl vs TMZ 0.04825 2.557 No ns -0.01376 to 0.1103 
PEG+CTS+TMZ vs PPG+CTS+TMZ 0.1825 9.671 Yes *** 0.1205 to 0.2445 
PEG+CTS+TMZ vs CTS+TMZ -0.07200 3.815 Yes * -0.1340 to -0.009987 
PEG+CTS+TMZ vs TMZ -0.3420 18.12 Yes *** -0.4040 to -0.2800 
PPG+CTS+TMZ vs CTS+TMZ -0.2545 13.49 Yes *** -0.3165 to -0.1925 
PPG+CTS+TMZ vs TMZ -0.5245 27.79 Yes *** -0.5865 to -0.4625 
CTS+TMZ vs TMZ -0.2700 14.31 Yes *** -0.3320 to -0.2080 
 
GM1 
Bonferroni's Multiple Comparison Test 
Mean 
Diff. t 
Significant? 
P < 0.05? Summary 95% CI of diff 
Ctrl vs PEG+CTS+TMZ 0.4933 10.53 Yes *** 0.3394 to 0.6471 
Ctrl vs PPG+CTS+TMZ 0.6788 14.49 Yes *** 0.5249 to 0.8326 
Ctrl vs CTS+TMZ 0.5603 11.96 Yes *** 0.4064 to 0.7141 
Ctrl vs TMZ 0.1325 2.829 No ns -0.02138 to 0.2864 
PEG+CTS+TMZ vs PPG+CTS+TMZ 0.1855 3.961 Yes * 0.03162 to 0.3394 
PEG+CTS+TMZ vs CTS+TMZ 0.0670 1.431 No ns 
-0.08688 to 
0.2209 
PEG+CTS+TMZ vs TMZ -0.3608 7.704 Yes *** -0.5146 to -0.2069 
PPG+CTS+TMZ vs CTS+TMZ -0.1185 2.531 No ns -0.2724 to 0.03538 
PPG+CTS+TMZ vs TMZ -0.5463 11.66 Yes *** -0.7001 to -0.3924 
CTS+TMZ vs TMZ -0.4278 9.134 Yes *** -0.5816 to -0.2739 
 
HUVEC 
Bonferroni's Multiple Comparison Test Mean Diff. t 
Signific
ant? P 
< 0.05? 
Summar
y 95% CI of diff 
Ctrl vs PEG+CTS+TMZ 0.06200 3.918 Yes * 0.01001 to 0.1140 
Ctrl vs PPG+CTS+TMZ 0.1303 8.232 Yes *** 0.07826 to 0.1822 
Ctrl vs CTS+TMZ -0.01775 1.122 No ns -0.06974 to 0.03424 
Ctrl vs TMZ 0.02625 1.659 No ns -0.02574 to 0.07824 
PEG+CTS+TMZ vs PPG+CTS+TMZ 0.06825 4.313 Yes ** 0.01626 to 0.1202 
PEG+CTS+TMZ vs CTS+TMZ -0.07975 5.040 Yes ** -0.1317 to -0.02776 
PEG+CTS+TMZ vs TMZ -0.03575 2.259 No ns -0.08774 to 0.01624 
PPG+CTS+TMZ vs CTS+TMZ -0.1480 9.354 Yes *** -0.2000 to -0.09601 
PPG+CTS+TMZ vs TMZ -0.1040 6.573 Yes *** -0.1560 to -0.05201 
CTS+TMZ vs TMZ 0.04400 2.781 No ns -0.007993 to 0.09599 
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A 
 
B 
Figure 2 (A) 
A typical pre-apoptotic cell after 24h incubation 
with chitosan+TMZ (PlasDIC phase contrast, 
magnification 400x),  and (B) in comparison with 
control (cells culture without chitosan+TMZ),(white 
light microscopy, PlasDIC contrast phase, 
magnification 400x) 
 
 
After cell GM1 treatement with 
chitosan+TZM autophagic cells were 
observed. 
 
 
Figure 3 
Autophagic cell GM1with intracytoplasmic vacuoles 
it was observed for chitosan+TZM nanoparticles. 
(phase contrast, magnification x400) 
Discussion and conclusion 
Long-term survival of patients 
diagnosed with high-grade gliomas 
remains poor, with population-based 
studies estimating that the 3-year survival 
rate is under 5%. [22-25]. Conventional 
treatment for newly diagnosed malignant 
gliomas was traditionally consisted of 
initial surgical resection followed by 
fractionated external beam RT, with or 
without chemotherapy usually using 
regimens containing alkylating agents. 
Until recently the benefit of chemotherapy 
in this setting remained controversial but 
TMZ, an oral alkylating agent, has proven 
to be efficient, primarily in the recurrent 
setting.  
The failure of current approaches to the 
treatment of malignant gliomas has been 
attributed to the existence of a sub-
population of cancer cells malignant 
glioma cancer stem cells (CSCs), which 
have the ability to withstand 
chemotherapeutics and ionizing radiation 
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based on certain of their unique properties: 
high expression of anti-apoptotic proteins, 
high expression of ABC pumps, and 
remarkable DNA repair capability.[13-15] 
Traditional therapies, such as DNA 
alkylating or methylating drugs along with 
radiation oncology treatments, have low 
treatment efficacy for these cell types. 
More complex treatments capable of 
overcoming the CSCs ability to eliminate 
anti-cancer drugs and perform other 
protective functions are therefore critically 
needed. For this reason, a combination of 
traditional treatments and nanotechnology-
based approaches offers attractive 
possibilities. More efficient and less toxic 
therapeutics that can cross the CSCs 
protective barriers are urgently needed. In 
this context, nanomaterials could play an 
important role based on their unique 
electronic, optical, magnetic, and structural 
properties that are found neither in bulk 
materials nor in single molecules and 
which are necessary to develop advanced 
cancer treatments. 
Similarities between the self-renewal 
mechanisms of stem cells and cancer cells 
have led to the new concept of cancer stem 
cells (CSCs). Over the course of the past 
10-15 years, there has been increasing 
evidence to support the cancer stem cell 
hypothesis, which postulates that CSCs are 
responsible for tumor initiation, metastasis, 
and resistance to treatment. It is now 
generally believed that a tumor has its 
origin in CSCs, which come either from 
transformed tissue stem cells or from 
transformed progenitor cells that have 
regained self-renewal activity.[16] These 
rare CSCs could be crucial in controlling 
and curing cancer: through asymmetric 
division, CSCs drive tumor growth and 
evade therapy with the help of traits shared 
with normal stem cells such as quiescence, 
self-renewal ability, and multidrug 
resistance pump activity.[17] These cells 
were first identified in hematologic 
cancers, but recently have been isolated 
from solid tumors.  CSCs are tumor 
initiating cells in immunocompromised 
mice and have the ability to generate 
heterogeneous cancer cell populations.[18]  
The gold standard assay to determine 
whether a stem cell is or not a CSC 
involves serial transplantation in animal 
models. Potential surface markers of CSCs 
include the following: CD133, aldehyde 
dehydrogenase 1 (ALDH1), CD44, and 
CD24. Efflux of Hoechst or Rhodamine 
dyes, also referred to as Side Population 
(SP), have also been used to identify 
putative CSCs. However, these markers 
have certain limitations in that they fail to 
identify all CSCs and merely designate a 
subpopulation that is enriched for 
clonogenic and tumorigenic activity. Also, 
not all cells with a CSC marker phenotype 
behave as CSCs. Most markers for 
separating CSCs were chosen due to their 
expression on normal stem cells of certain 
tissues, and, interestingly, there are a 
number of molecules that are commonly 
expressed in normal and cancer stem cells 
that lead to different phenomena 
depending on the local environment.[19] 
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Using Bonferroni’s Multiple 
Comparison Test, we found statistically 
significant results (P<0.05) between the 
CSCs (control) and the CTR+ 
PEG+CTS+TMZ  (95 CI of 0,3394 to 
0,6471), CTR+PPG-CTS-TMZ (95% Cl of 
0,5249 to 0,83260), CTR+CTS-TMZ (95% 
of 0,4064 to 0,7141). When one or more 
initiating genetic changes appeared at the 
progenitor level, all of the downstream 
cells continued this change. In one 
particular case, it is possible that a 
daughter cell acquired not only the 
properties of the stem cell, but also the 
additional alterations that allow the glioma 
to progress to the next step and invade 
surrounding tissues. Due to the small 
population of glioblastoma-derived stem 
cells, the malignant gliomas have a 
negative response to various conventional 
treatments.[20] The killing efficiency of 
the  PEG+CTS+TMZ, PPG-CTS-TMZ, 
CTS-TMZ nanostructures on glioblastoma-
derived stem cells is better compared with 
the drug temozolomide, alone.  
Our proposed nanoscaled drug delivery 
system offers also a new chemotherapy 
strategy for patients diagnosed with 
unresectable or recurrent malignant 
gliomas. Current therapies are not yet 
curative, as CSCs may survive as a result 
of the increased efflux of chemotherapy 
agents due to ABCG2 cell membrane 
proteins and increased DNA repair.[21] 
Cancer cells are very complex biological 
structures that perform functions ranging 
from invasion or metastasis to the 
elimination of anticancer drugs from the 
cell membrane. Although the exact 
mechanisms need to be explored further, 
combining advances in fundamental 
oncology and nanotechnology offers the 
opportunity to significantly impact future 
diagnostics and therapeutics. We have 
shown that drug delivery vectors based on 
chitosan and polymers have the ability to 
deliver temozolomide (TMZ), a cytostatic 
drug, to treat  malignant gliomas. Our 
studies have shown that a novel drug 
delivery has low toxicity and the ability to 
internalize TMZ. 
Malignant gliomas are highly infiltrative 
and lethal cancers of the central nervous 
system. The highly infiltrative nature of 
glioma cells often renders a complete 
surgical removal impossible and inevitably 
will lead to tumor recurrence. 
The attention of the scientific 
community is currently focused on 
nanoparticles, a novel vector for the 
delivery of anticancer drugs to target 
cancer cells. These particles have many 
advantages which recommend it over 
classically administered drugs. Due to their 
submicroscopic size and modifiability, 
nanoparticles have an enhanced access to 
cancer cells, being able to maintain high 
concentrations of drugs in target tissues. 
Because of their special distribution, drug-
loaded nanoparticles may even have a 
decreased risk of systemic adverse effects 
which normally occur at increased drug 
doses, while locally maintaining effective 
concentrations. Nanoparticles loaded with 
various cytostatics may prove to have 
numerous additional advantages. The 
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increased drug concentrations may also be 
explained by the facilitated penetration of 
the particles in the tumor through 
endocytosis, which has the advantage of 
bypassing the transporter- mediated drug 
internalization systems. Moreover, the 
intracellular drug concentration increases 
in spite of tumor cell multidrug resistance 
protein activity, which may result in better 
tumor-level effect of the drug in spite of 
multidrug resistant tumor phenotype. 
Another positive viewpoint of using 
nanoparticles is their capacity to cross the 
blood brain barrier, which shapes new 
directions for drug delivery into the brain. 
Most drugs partially cross the blood brain 
barrier, but its incorporation into 
nanoparticles may enhance its passage and 
increase the relative amount of drug 
reaching brain tissue. Therefore, the use of 
loaded nanoparticles could be of 
paramount importance for glioblastomas, 
aggressive tumors with a very dismal 
prognosis, for which temozolomide has 
been entitled “the most clinically relevant 
drug ever reported for targeting of glioma-
initiating cells”.[25] 
Nanostructures  like  chitosan, PEG, 
PPG are useful as vectors for 
temozolomide transport. 
Our study shows a net decrease of cell 
population by treating them with drug-
nanostructures. Cell population decrease 
was more important in tumor cell cultures 
(GM1) compared with normal cells 
fibroblasts (HFL) or endothelial cells 
(HUVEC). The best response was obtained 
for chitosan-Tz, considering that drug 
chemotherapy should be  aggressive on 
tumor cells and less aggressive on normal 
cells. 
Our study tries to find new drugs for 
the treatment of glioblastoma. Results 
must be confirmed by in vivo studies. 
Despite combined therapy (surgery, 
radiotherapy, chemotherapy), currently 
median patient survival is 10-12 months. 
The key to improving life expectancy could 
be an effective therapy targeted, 
customized for each case. An increasingly 
important role will be new methods of 
treatment such as immunotherapy, gene 
therapy or nanotherapy. 
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